Juan Andres Net Worth

The estimated Net Worth of Juan Andres is at least $5.04 Million dollars as of 28 December 2022. Mr. Andres owns over 2,000 units of Moderna Inc stock worth over $1,176,987 and over the last 6 years he sold MRNA stock worth over $0. In addition, he makes $3,862,570 as Chief Technical Operations and Quality Officer at Moderna Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Andres MRNA stock SEC Form 4 insiders trading

Juan has made over 144 trades of the Moderna Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of MRNA stock worth $41,860 on 28 December 2022.

The largest trade he's ever made was exercising 127,500 units of Moderna Inc stock on 13 May 2020 worth over $1,556,775. On average, Juan trades about 6,712 units every 7 days since 2019. As of 28 December 2022 he still owns at least 14,803 units of Moderna Inc stock.

You can see the complete history of Mr. Andres stock trades at the bottom of the page.

Juan Andres biography

Juan Andres serves as Chief Technical Operations and Quality Officer of the Company. He joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from 2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.

What is the salary of Juan Andres?

As the Chief Technical Operations and Quality Officer of Moderna Inc, the total compensation of Juan Andres at Moderna Inc is $3,862,570. There are 3 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of $8,948,210.

How old is Juan Andres?

Juan Andres is 55, he's been the Chief Technical Operations and Quality Officer of Moderna Inc since 2018. There are 9 older and 9 younger executives at Moderna Inc. The oldest executive at Moderna Inc is Elizabeth Tallett, 71, who is the Director.

What's Juan Andres's mailing address?

Juan's mailing address filed with the SEC is RADNOR CORPORATE CENTER, BUILDING ONE,, SUITE 200, 100 MATSONFORD ROAD, RADNOR, PA, 19087.

Insiders trading at Moderna Inc

Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein, and Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.

What does Moderna Inc do?

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a

Complete history of Mr. Andres stock trades at Evelo Biosciences Inc, Moderna Inc, and Avantor

Moderna Inc executives and stock owners

Moderna Inc executives and other stock owners filed with the SEC include:

• Stephane Bancel,
  Chief Executive Officer, Director
• Stephen Hoge,
  President
• Tal Zvi Zaks,
  Chief Medical Officer
• Juan Andres,
  Chief Technical Operations and Quality Officer
• Stephane Bancel,
  CEO & Director
• Stéphane Bancel,
  CEO & Director
• Dr. Stephen Hoge M.D.,
  Pres
• Dr. Stephen Hoge,
  Pres
• Juan Andres,
  Chief Technical Operations & Quality Officer
• David W. Meline,
  CFO & Principal Accounting Officer
• Francois Nader,
  Non-Executive Independent Director
• Noubar Afeyan,
  Non-Executive Independent Chairman of the Board, Co-Founder
• Israel Ruiz,
  Non-Executive Independent Director
• Robert Langer,
  Non-Executive Independent Director
• Stephen Berenson,
  Non-Executive Independent Director
• Paul Sagan,
  Non-Executive Independent Director
• Dr. Noubar B. Afeyan Ph.D.,
  Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board
• Elizabeth Tallett,
  Director
• Ray Jordan,
  Chief Corporate Affairs Officer
• Marcello Damiani,
  Chief Digital and Operational Excellence Officer
• Lori Henderson,
  General Counsel, Company Secretary
• Tracey Franklin,
  Chief Human Resource Officer
• David Meline,
  Chief Financial Officer
• Colleen Hussey,
  Sr. Mang. of Corp. Communications
• Shannon Thyme Klinger,
  Chief Legal Officer & Corp. Sec.
• Lori M. Henderson J.D., Esq.,
  Gen. Counsel & Corp. Sec.
• Lavina Talukdar CFA,
  Sr. VP & Head of Investor Relations
• Dr. Melissa J. Moore,
  Chief Scientific Officer & Member of Scientific Advisory Board
• Dr. John V. W. Reynders,
  Chief Information Officer
• Lorence H. Kim,
  Chief Financial Officer
• Elizabeth G Nabel,
  Director
• Noubar Flagship Ventures Fu...,
  
• Shannon Thyme Klinger,
  Chief Legal Officer
• Jennifer Ling Lee,
  Chief Accounting Officer
• Sandra Horning,
  Director
• Peter Barton Hutt,
  Director
• Moncef Slaoui,
  Director
• Ventures Fund Iv General Pa...,
  
• Edwin M Jr Kania,
  10% owner
• Ventures Fund Iv General Pa...,
  
• Goff Corinne Le,
  Chief Commercial Officer
• Paul Burton,
  Chief Medical Officer
• James M Mock,
  Chief Financial Officer
• Arpa Garay,
  Chief Commercial Officer
• David M. Rubenstein,
  Director